Efficacy and Safety of Dual Targeted Therapy for Partially or Non-responsive Inflammatory Bowel Disease: A Systematic Review of the Literature.

Authors:
Berinstein EM; Sheehan JL; Jacob J; Steiner CA; Stidham RW and 7 more

Journal:
Dig Dis Sci

Publication Year: 2023

DOI:
10.1007/s10620-023-07837-0

PMCID:
PMC9942632

PMID:
36807832

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Dig Dis Sci

Abbreviation: Dig Dis Sci

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Gastroenterology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Characterization of Duodenal Microbiota in Patients with Acute Pancreatitis and Healthy Controls.
Zhao MQ; Cui MY; Jiang QL and 3 more (2023) - Transparency Score: 4/6
Cluster-Analytic Identification of Clinically Meaningful Subtypes in MCAS: The Relevance of Heat an…
Häder T; Molderings GJ; Klawonn F and 3 more (2023) - Transparency Score: 3/6
Co-design and Consultation Ensure Consumer Needs Are Met: Building an eHealth Platform for Children…
Pipicella JL; Vernon-Roberts A; Dutt S and 4 more (2023) - Transparency Score: 3/6
Comparisons Between Endoscopic Band Ligation, Radiofrequency Ablation and Endoscopic Thermal Therap…
Che CC; Shiu SI; Ko CW and 2 more (2023) - Transparency Score: 3/6
Developing a Novel Case-Based Gastroenterology/Hepatology Online Resource for Enhanced Education Du…
Goodman MC; Chesner JH; Pourmand K and 3 more (2023) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
2/6
33.3% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Conflict of interestPDRH received consulting fees from AbbVie, Amgen, Genentech, and Pfizer. RWS received consulting fees from AbbVie, Janssen, Takeda, Merck, Gilead, Eli Lily, Exact Science, Evergreen Pharmaceuticals, Corrona LLC. JAB received consulting fees from BUHLMANN Diagnostics Corp. All other authors report no relevant disclosures. Conflict of interest PDRH received consulting fees from AbbVie, Amgen, Genentech, and Pfizer. RWS received consulting fees from AbbVie, Janssen, Takeda, Merck, Gilead, Eli Lily, Exact Science, Evergreen Pharmaceuticals, Corrona LLC. JAB received consulting fees from BUHLMANN Diagnostics Corp. All other authors report no relevant disclosures."

Funding Disclosure
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025